Ivantis, Inc. is a company dedicated to the development of new and innovative solutions for glaucoma. Current therapies for primary open angle glaucoma (POAG) include eye drops, laser therapy, and surgery. But each of these has its limitations. Glaucoma remains the leading cause of blindness worldwide, in need of better treatment alternatives. It is our goal to develop new and effective solutions for ophthalmology specialists and the 70 million people worldwide who are affected by this debilitating and sight-stealing disease.
What's New
Ivantis Announces Completion of $27 MM Financing for Novel Glaucoma Procedure.
Read more »
One-year Results of a Schlemm's Canal Microstent for IOP Reduction in Open Angle Glaucoma
Read more »
Ivantis Wins "Best of Session" Award at ASCRS
Ivantis recently won a Blue Ribbon award for our presentation on the use of Hydrus Technology. See it by clicking here.
